Adenoviruses as vaccine vectors

Tatsis, Nia; Ertl, Hildegund C. J.

doi:10.1016/j.ymthe.2004.07.013

Cited by 584 publications

(483 citation statements)

References 129 publications

Supporting

Mentioning

460

Contrasting

Unclassified

Order By: Relevance

“…Adenoviral vectors of human and, more recently, chimpanzee serotypes have been described as attractive vaccine vectors as they induce both innate and adaptive responses [30,31], and here we demonstrate that they can also induce responses in the lymphoid tissues of the intestinal mucosa. This implies that imprinting by mucosal dendritic cells is not an absolute requirement for primed T cells to migrate to the gut [32,33].…”

Section: Discussionsupporting

confidence: 61%

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Lin

Cun

Harris-McCoy

et al. 2007

Vaccine

View full text Add to dashboard Cite

Gut-associated lymphoid tissue (GALT) is the primary replication site for HIV-1, resulting in a pronounced CD4 + T cell loss in this tissue during primary infection. A mucosal vaccine that generates HIV-specific CD8 + T cells in the gut could prevent the establishment of founder populations and broadcasting of virus. Here, we immunized mice orally and systemically with a chimpanzee derived adenoviral vector expressing HIV gag (AdC68gag) and measured frequencies of gag-specific interferon-gamma (IFN-γ) producing CD8 + T cells in the GALT. A single oral administration was inefficient at eliciting responses in the mesenteric lymph nodes and Peyer's Patches, while a single intramuscular administration elicited strong systemic and detectable mucosal responses. The gagspecific CD8 + T cell responses were present in both acute and memory phases following intramuscular administration.

show abstract

Section: Discussionsupporting

confidence: 61%

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Lin

Cun

Harris-McCoy

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…12,13 Adenovirus vectors were shown to be capable of transducing and expressing transgenes in both human or mouse DCs. 14,15 However, their applications are limited due to the high prevalence of pre-existing immunity to adenoviral proteins. 16,17 Retroviral vectors based on murine leukemia virus have also been used for antigen delivery, 18 however, these murine leukemia virusbased vectors only infect dividing cells.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma

Yang

Liang

et al. 2011

Cancer Gene Ther

View full text Add to dashboard Cite

Lentivectors are potential vaccine delivery vehicles because they can efficiently transduce a variety of non-dividing cells, including antigen-presenting cells, and do not cause expression of extra viral proteins. To improve safety while retaining efficiency, a dendritic cell (DC)-specific lentivector was constructed by pseudotyping the vector with an engineered viral glycoprotein derived from Sindbis virus. We assessed the level of anti-tumor immunity conferred by this engineered lentivector encoding the melanoma antigen gp100 in a mouse model. Footpad injection of the engineered lentivectors results in the best antigen-specific immune response as compared with subcutaneous and intraperitoneal injections. A single prime vaccination of the engineered lentivectors can elicit a high frequency (up to 10%) of gp100-specific CD8 þ T cells in peripheral blood 3 weeks after the vaccination and this response will be maintained at around 5% for up to 8 weeks. We found that these engineered lentivectors elicited relatively low levels of anti-vector neutralizing antibody responses. Importantly, direct injection of this engineered lentivector inhibited the growth of aggressive B16 murine melanoma. These data suggest that DC-specific lentivectors can be a novel and alternative vaccine carrier with the potential to deliver effective anti-tumor immunity for cancer immunotherapy.

show abstract

“…Recombinant adenoviruses (Ad), originally used as vehicles for gene replacement therapy, 1 have become favorite vaccine carriers for delivery of genes derived from pathogens [2][3][4] or tumors. 5 They elicit strong and sustained transgene product-specific immune responses upon delivery of a single dose given either systemically 6,7 or via mucosal routes.…”

Section: Introductionmentioning

confidence: 99%

Chimpanzee-origin adenovirus vectors as vaccine carriers

et al. 2005

View full text Add to dashboard Cite

Vaccines based on replication-defective adenoviral vectors are being developed for infectious agents and tumorassociated antigens. Early work focused on vaccines derived from a common human serotype of adenovirus, that is, adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies against AdHu5 virus, present in a large percentage of the human population, dampen the efficacy of vaccines based on this carrier. To circumvent this problem, we generated vectors derived from chimpanzee adenoviruses.Here we describe some basic parameters of vectors derived from chimpanzee adenoviruses C68 and C7, including growth characteristics, yields of infectious particles, effects of additional deletions in E3 and E4 and lengths of the inserted foreign sequence as they relate to the suitability for their eventual development as vaccine carriers for clinical use.

show abstract

Adenoviruses as vaccine vectors

Cited by 584 publications

References 129 publications

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut

Dendritic cell-directed lentivector vaccine induces antigen-specific immune responses against murine melanoma

Chimpanzee-origin adenovirus vectors as vaccine carriers

Contact Info

Product

Resources

About